Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Fujifilm To Enter Radiopharmaceuticals
by Michael McCoy
November 10, 2014
| A version of this story appeared in
Volume 92, Issue 45
Fujifilm will spend more than $50 million to enter the market for positron emission tomography (PET) radiopharmaceuticals used in disease diagnosis. The Japanese firm will use the money to establish labs in Ibaraki City and Kawasaki City, Japan, where it will research radiolabeled compounds that can help diagnose Alzheimer’s and other diseases. Last month Fujifilm agreed to help Eli Lilly & Co. win Japanese approval for florbetapir, which is approved in the U.S. to detect brain plaques associated with Alzheimer’s.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X